source
- FDA grants accelerated approval to Bristol Myers' Zenbexus, first CELMoD for multiple myelomaThe FDA issued an accelerated approval on Thursday for Zenbexus, a multiple myeloma therapy that Bristol Myers Squibb inherited from its Celgene acquisition. Zenbexus belongs to a new class of pro…
- Safety concerns emerge as radiopharmaceuticals advance in cancer trialsRadiopharmaceuticals are being hailed for their ability to deliver radiation directly to tumours, potentially sparing surrounding healthy tissue and improving cancer therapy. However, as more cand…